Upcoming Investor Conferences

RNS Number : 5088B

MaxCyte, Inc.

14 February 2022

 

MaxCyte to Participate in Upcoming Investor Conferences

GAITHERSBURG, MD, February 14, 2022 - MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT, MXCN), a leading commercial cell-engineering company focused on providing enabling platform technologies to advance innovative cell-based research as well as next-generation cell therapeutic discovery, development and commercialization, today announced Company management will participate in the following virtual investor conferences:

· BIO CEO & Investor Conference

Presentation on Tuesday, February 15^th

· BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference

Fireside chat on Thursday, February 17^th at 3:00 p.m. Eastern Time

· Cowen Annual Healthcare Conference

Fireside chat on Monday, March 7^th at 9:50 a.m. Eastern Time

Live and archived webcasts of the events will be available on the "Events" section of the MaxCyte investor relations website at https://investors.maxcyte.com/ . BTIG hosted events are intended for prospective and existing BTIG clients only. To listen to the live event, please contact your BTIG representative with interest.

About MaxCyte

MaxCyte is a leading commercial cell-engineering company focused on providing enabling platform technologies to advance innovative cell-based research as well as next-generation cell therapeutic discovery, development and commercialization. Over the past 20 years, we have developed and commercialized our proprietary Flow Electroporation® platform, which facilitates complex engineering of a wide variety of cells. Our ExPERT™ platform, which is based on our Flow Electroporation technology, has been designed to support the rapidly expanding cell therapy market and can be utilized across the continuum of the high-growth cell therapy sector, from discovery and development through commercialization of next-generation, cell-based medicines. The ExPERT family of products includes: four instruments, the ATx™, STx™, GTx™, and VLx™; a portfolio of proprietary related processing assemblies or disposables; and software protocols, all supported by a robust worldwide intellectual property portfolio.

MaxCyte Contacts:

US IR Adviser Gilmartin Group David Deuchler, CFA	[phone] [e-mail]
Nominated Adviser and Joint Corporate Broker Panmure Gordon Emma Earl / Freddy Crossley Corporate Broking Rupert Dearden	[phone]
UK IR Adviser Consilium Strategic Communications Mary-Jane Elliott Chris Welsh	[phone] [e-mail]

 

END

 

 

MSCSFAFADEESELE